Several new treatments for sleep apnea have emerged in recent years, giving people real alternatives to the CPAP machine that has long been the default. These range from a small implant that stimulates a nerve in your tongue to weight-loss medications originally designed for diabetes, plus oral drugs still working through clinical trials. The options reflect a shift in how sleep apnea is treated: instead of one device fits all, doctors can now match treatment to what’s actually causing your airway to collapse.
Why Alternatives to CPAP Matter
CPAP works well when people use it consistently, but a large portion don’t. Long-term data shows that only about 45% of patients achieve high adherence after two years of therapy. Another 39% stop using it entirely, and 16% use it so infrequently that it provides little benefit. The mask, the noise, the dryness, the feeling of pressure on your face at night: these aren’t minor inconveniences for many people. They’re deal-breakers. That gap between CPAP’s effectiveness in a lab and its effectiveness in real bedrooms is exactly what newer treatments are trying to close.
Hypoglossal Nerve Stimulation (Inspire)
The most established new option is a small device implanted under the skin of your chest, similar in size to a pacemaker. It’s called the Inspire system, and it works by sending mild electrical pulses to the hypoglossal nerve, which controls your tongue. When the device senses you’re breathing in, it gently moves your tongue forward to keep your airway open. You turn it on with a remote before bed and turn it off in the morning.
The results are striking. In clinical studies, total apneas dropped from a median of 30 events per night down to 2. The overall number of breathing disruptions per hour fell from a median of 23.5 to 4.8, which moves most patients from moderate-to-severe sleep apnea into the mild or normal range. These improvements held at roughly nine months after implantation, and the landmark STAR trial showed sustained benefit at 12 months.
The FDA recently expanded who qualifies. The upper BMI limit increased from 32 to 40, meaning more people with obesity are now eligible. The severity ceiling also rose, with patients now qualifying if they have up to 100 breathing disruptions per hour (previously capped at 65). You need to be at least 18, have moderate-to-severe sleep apnea with an AHI of 15 or higher, and have tried CPAP without success. Teens aged 13 to 18 with Down syndrome and severe sleep apnea can also qualify. The implant requires a short surgical procedure, and most people go home the same day.
Weight-Loss Medications That Treat Sleep Apnea Directly
The connection between obesity and sleep apnea has always been clear: excess tissue around the neck and throat narrows the airway. What’s new is that powerful weight-loss drugs are now being studied specifically as sleep apnea treatments, not just as a side benefit of losing weight.
Tirzepatide, a medication already approved for type 2 diabetes and weight management, was tested in people with both obesity and moderate-to-severe obstructive sleep apnea in the SURMOUNT-OSA trials published in the New England Journal of Medicine. The drug significantly reduced the number of breathing disruptions per hour, lowered the amount of time patients spent with dangerously low oxygen levels, decreased a blood marker of inflammation, and brought down systolic blood pressure. Patients also reported better sleep quality and less daytime impairment. This is notable because it treats two conditions simultaneously, and for people whose sleep apnea is primarily driven by weight, it may address the root cause rather than just managing the symptom.
An Oral Drug Designed Specifically for Sleep Apnea
No pill currently has FDA approval to treat obstructive sleep apnea, but one candidate is deep into phase 3 trials. AD109 combines two existing compounds in a single capsule taken at bedtime: one that relaxes involuntary muscle contractions in the airway and another that increases the activity of nerve signals keeping your airway muscles toned during sleep. The idea is to prevent the airway from collapsing by working on the muscles and nerves directly, without any device or mask.
The phase 3 trials are measuring whether AD109 reduces breathing disruptions per hour and improves fatigue over 26 weeks compared to placebo. Researchers are also tracking how many patients achieve at least a 50% drop in their breathing disruptions. If the trials succeed, this could become the first pill approved to treat the condition, which would be a significant shift for the roughly 30 million Americans with obstructive sleep apnea.
Nasal Valve Devices
For people with milder sleep apnea who want something far simpler than CPAP, nasal expiratory positive airway pressure (EPAP) devices offer a low-tech option. These are small, disposable or reusable valves that fit over or inside your nostrils. They create very little resistance when you breathe in but generate back-pressure when you breathe out. That outward pressure splints your airway open, making it more resistant to collapse on the next breath in.
In a randomized controlled trial, EPAP devices reduced breathing disruptions by about 53% in the first week, bringing the median number of events per hour down from 13.8 to 5.0. At three months, the reduction held at roughly 43%. These aren’t as powerful as CPAP for severe cases, but for mild-to-moderate sleep apnea, the simplicity is appealing: no machine, no electricity, no noise, and nothing strapped to your head.
Positional Therapy Devices
Many people experience sleep apnea primarily when lying on their back, because gravity pulls the tongue and soft tissues into the airway. Positional therapy has traditionally meant taping a tennis ball to the back of your shirt, but modern versions use small wearable devices that vibrate gently when you roll onto your back, training you to stay on your side without fully waking you.
For people with mild-to-moderate positional sleep apnea, these devices reduce breathing disruptions at rates comparable to CPAP. Daytime sleepiness scores drop from abnormal to normal ranges. And compliance tends to be better than CPAP, where studies consistently show that 29% to 83% of users fail to meet the minimum four-hours-per-night threshold, depending on how long you follow them.
Surgery: What’s Changed
Surgical options have been around for decades, but they’ve become more refined. The most common procedure, uvulopalatopharyngoplasty (UPPP), removes or repositions excess tissue in the throat. A broader approach combines palate surgery with nasal surgery to open multiple points of obstruction at once.
Both approaches produce significant short-term improvements. UPPP reduces breathing disruptions and improves sleep efficiency, while the combined approach improves both airway obstruction scores and oxygen levels during sleep. Self-reported snoring improves dramatically after either surgery. The key limitation is durability: snoring symptoms tend to return to pre-surgery levels after about 3.9 to 5.3 years, compared to roughly 6.2 years for CPAP users. However, the actual breathing metrics (the number of disruptions and oxygen levels) appear to hold steady over time, suggesting that the structural benefit persists even as snoring gradually creeps back.
How AI Is Changing Diagnosis
Getting diagnosed has traditionally required spending a night in a sleep lab hooked up to dozens of sensors, a process called polysomnography. It’s expensive, inconvenient, and has long wait times in many areas. Artificial intelligence is starting to change this by analyzing simpler data collected at home.
AI models have been trained to detect sleep apnea using signals like breathing sounds, blood oxygen patterns, and airflow measurements from portable home devices. A systematic review of these tools found that the best-performing models achieve sensitivity above 90% and specificity above 95%, meaning they correctly identify most people who have the condition while rarely flagging people who don’t. Not all models perform equally well, with accuracy varying depending on what type of data they analyze, but the trajectory is clear: diagnosing sleep apnea is becoming faster and more accessible, which matters because the condition remains significantly underdiagnosed.
Choosing the Right Option
The best new treatment depends on what’s driving your sleep apnea. If excess weight is the primary factor, tirzepatide or similar medications may address the root cause. If your airway collapses because the tongue falls back during sleep, hypoglossal nerve stimulation targets that mechanism directly. If your apnea mostly happens on your back, a positional device may be all you need. And if you have mild-to-moderate apnea and simply can’t tolerate anything on your face, nasal valves offer a minimalist approach.
What’s genuinely different now is that “I can’t use CPAP” is no longer a dead end. It’s the starting point for a conversation about which of several proven or near-proven alternatives fits your body, your severity level, and your life.